
U.S. FDA Approved Pfizer’s BESPONSA® : New Treatment For Relapsed or Refractory Acute Lymphoblastic Leukemia
U.S. FDA Approved Pfizer’s BESPONSA® : New Treatment For Relapsed or Refractory Acute Lymphoblastic Leukemia By: Pfizer News Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has approved BESPONSA® (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).1BESPONSA was reviewed [..]